Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-22
DOI
10.1038/s41467-017-00263-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identifying differential networks based on multi-platform gene expression data
- (2017) Le Ou-Yang et al. Molecular BioSystems
- The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology
- (2017) Nicholas C. Dracopoli et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 years
- (2016) S. B. Kaye ANNALS OF ONCOLOGY
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
- (2016) Joyce F. Liu et al. CLINICAL CANCER RESEARCH
- Evolving Approaches in Research and Care for Ovarian Cancers
- (2016) Douglas A. Levine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mitochondria and Cancer
- (2016) Wei-Xing Zong et al. MOLECULAR CELL
- Evolving Paradigms in Research and Care in Ovarian Cancers
- (2016) Beth Y. Karlan et al. OBSTETRICS AND GYNECOLOGY
- Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
- (2016) S Baig et al. Cell Death & Disease
- Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status
- (2016) F. Coscia et al. Nature Communications
- Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
- (2016) Dong Wang et al. Oncotarget
- Mitochondrial apoptosis: killing cancer using the enemy within
- (2015) J Lopez et al. BRITISH JOURNAL OF CANCER
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- (2015) Joan Montero et al. CELL
- Ovarian and cervical cancer patient derived xenografts: The past, present, and future
- (2015) Jonathan D. Boone et al. GYNECOLOGIC ONCOLOGY
- Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research
- (2015) Kevin M. Elias et al. GYNECOLOGIC ONCOLOGY
- In vivo tumor growth of high-grade serous ovarian cancer cell lines
- (2015) Anirban K. Mitra et al. GYNECOLOGIC ONCOLOGY
- Erratum: Corrigendum: Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Adaptive stress signaling in targeted cancer therapy resistance
- (2015) E Pazarentzos et al. ONCOGENE
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
- (2015) D. M. Janzen et al. Nature Communications
- Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer
- (2015) Zachary C. Dobbin et al. Oncotarget
- Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer
- (2014) Jens C. Hahne et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced
- (2014) Abdelghani Jebahi et al. CANCER LETTERS
- Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
- (2014) F. Ricci et al. CANCER RESEARCH
- Tumorgrafts asIn VivoSurrogates for Women with Ovarian Cancer
- (2014) S. John Weroha et al. CLINICAL CANCER RESEARCH
- Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: Anex vivoexperiment in human serous ovarian carcinoma
- (2014) Stéphanie Lheureux et al. INTERNATIONAL JOURNAL OF CANCER
- Better Therapeutic Trials in Ovarian Cancer
- (2014) M. A. Bookman et al. JNCI-Journal of the National Cancer Institute
- Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
- (2014) Monique D. Topp et al. Molecular Oncology
- Cancer Systems Biology: a peek into the future of patient care?
- (2014) Henrica M. J. Werner et al. Nature Reviews Clinical Oncology
- Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
- (2014) W Du et al. ONCOGENE
- A pan-cancer proteomic perspective on The Cancer Genome Atlas
- (2014) Rehan Akbani et al. Nature Communications
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
- (2014) Filip Janku et al. Cell Reports
- Targeting EGFR and PI3K pathways in ovarian cancer
- (2013) S Glaysher et al. BRITISH JOURNAL OF CANCER
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
- (2013) H. Ebi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Exploiting p70 S6 kinase as a target for ovarian cancer
- (2012) Carman KM Ip et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- FoxO transcription factors; Regulation by AKT and 14-3-3 proteins
- (2011) Guri Tzivion et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome
- (2011) Jia Huang et al. GENES CHROMOSOMES & CANCER
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
- (2011) Yoko S DeRose et al. NATURE MEDICINE
- Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells
- (2011) J. M. Stewart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
- (2011) T. N. Chonghaile et al. SCIENCE
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
- (2010) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer
- (2010) J. J. Wallin et al. Science Translational Medicine
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started